分类： health

Cuban President Miguel Díaz-Canel Bermúdez emphasized on Tuesday the importance of integrating Biomodulin T into primary health care across Cuban communities. During a meeting with health experts at the Palace of the Revolution, he urged that medical professionals be adequately trained to prescribe this innovative treatment. The discussion highlighted the significant role of Biomodulin T, a bovine thymus extract-based drug, in addressing immune dysfunction and recurrent infections, particularly among the elderly. Clinical trials involving nearly 9,000 nursing home residents demonstrated a remarkable reduction in acute respiratory infections (ARI) by over five times, and a 50% decrease in mortality risk compared to those outside such facilities. The drug also showed a 70% reduction in respiratory infection incidence among the elderly, a leading cause of death in Cuban nursing homes. Additionally, Biomodulin T has proven effective in oncology, rejuvenating patients’ immune systems when combined with chemotherapy and immunotherapy. It has also been successful in treating thymic hypoplasia in children, with 83% of treated children achieving normalized thymus size and function, and 71% showing clinical improvement. Given these promising results, President Díaz-Canel called for expedited efforts to incorporate Biomodulin T into national health strategies, especially in light of Cuba’s aging population. The drug, which gained prominence during the COVID-19 pandemic with over 1.9 million units distributed and more than 238,000 patients treated, has been recognized with two awards from the Academy of Sciences in 2022 for its efficacy in treating lung cancer and its immunomodulatory effects in older adults.

Cuban health authorities have provided a comprehensive update on the nation’s COVID-19 situation, revealing significant epidemiological data since the pandemic’s onset. Dr. Francisco Durán, the National Director of Epidemiology at the Ministry of Public Health, delivered the latest statistics during his regular televised briefing, offering a detailed breakdown of the country’s pandemic response.

According to the official figures, Cuba has recorded a cumulative total of 825,351 confirmed coronavirus cases since March 11, 2020, with the pandemic claiming 6,978 lives on the island nation. The current hospitalization numbers present a complex picture of the pandemic’s status, with 90,027 individuals receiving medical care in hospitals across the country.

The hospitalization data reveals three distinct patient categories: 46,548 individuals are classified as suspected cases undergoing observation and testing; 3,162 people are under formal epidemiological surveillance due to confirmed exposure risks; and 40,317 are confirmed active patients receiving treatment for COVID-19.

Testing capacity remains a critical component of Cuba’s pandemic response. Health officials reported that 53,249 laboratory samples were processed this Tuesday alone to detect the SARS-CoV-2 virus. This daily testing effort contributes to a substantial national total of 9,165,377 real-time PCR tests conducted since the pandemic began, demonstrating the country’s extensive diagnostic capabilities.

The regular briefings by Dr. Durán have become a cornerstone of Cuba’s public health communication strategy, providing transparent data to citizens and international observers alike. These updates offer valuable insights into both the historical progression and current status of the pandemic within Cuba’s unique healthcare system.

Cuba’s leading scientific institutions have achieved a significant breakthrough in COVID-19 vaccine development, with the Abdala immunogen demonstrating remarkable efficacy against the virus. According to official reports from Granma newspaper, the vaccine received emergency use authorization in July following rigorous clinical trials that established a 92.28% efficacy rate in disease prevention.

The vaccine’s effectiveness was confirmed during a critical period of Delta variant propagation across global populations, providing crucial data on its performance against this highly contagious strain. Dr. Marta Ayala, General Director of the Center for Genetic Engineering and Biotechnology (CIGB), provided important scientific clarification regarding the terminology: ‘Efficacy should not be confused with effectiveness, as the former is determined within the controlled environment of clinical studies under ideal research conditions, while effectiveness is analyzed in real-world circumstances.’

Cuban researchers from both CIGB and the Finlay Vaccine Institute have recently presented their comprehensive scientific findings to the World Health Organization. The submission includes complete documentation of the research methodology, formulation processes, production standards, testing protocols, and application results. This presentation marks a significant step toward obtaining international validation and WHO emergency use listing, which would facilitate global distribution and recognition of Cuba’s sovereign vaccine development capabilities.

Cuban health officials presented the nation’s advanced digital health strategy during the 59th Executive Council meeting of the Pan-American Health Organization (PAHO), highlighting how technological innovation has strengthened pandemic response capabilities. Dr. Ileana Morales, Director of Science and Technological Innovation at Cuba’s Ministry of Public Health (MINSAP), detailed how digital tools have enabled real-time data processing for more effective epidemiological management throughout the COVID-19 crisis.

Dr. Morales emphasized Cuba’s comprehensive approach to health information systems development, which centers on specialized training for professionals in technology and university programs. The country has made significant advancements in cutting-edge medical fields including medical robotics, precision medicine, nanoscience, and neuroscience—all disciplines that demand sophisticated data processing capabilities for large-volume information assimilation.

Karel Barthelemy, MINSAP’s Director of Information Technology and Communications, addressed the substantial challenges of digital transformation in healthcare, stressing the necessity for tailored designs that accommodate each nation’s unique characteristics. He outlined several operational computer solutions currently deployed in Cuba, including research platforms, laboratory results monitoring systems, hospital bed availability trackers, clinical laboratory information management, and vaccinated population databases.

A critical component of Cuba’s strategy involves employing Big Data analytics and mathematical modeling to predict viral behavior patterns within populations. These predictive tools enable health authorities to refine national response plans and continuously update patient care protocols based on empirical evidence.

Both officials emphasized the importance of regional cooperation, noting that successful implementation of digital transformation roadmaps across the Americas requires strengthened collaboration between PAHO and member states. Such partnerships would facilitate knowledge exchange and accelerate progress toward developing shared technological platforms that benefit the entire region.